Registration
Welcome address A. Klinakis (GR)
08.30-08.50: DNA resection, ssDNA gaps and PARP inhibitor sensitivity: Mechanisms and therapeutic opportunities W. Niedzwiedz (UK)
08.50-09.10: DNA damage and innate immune responses in health and disease G. Garinis (GR)
09.10-09.30: Beyond BRCA: why PARP inhibitors also kill ATM-deficient cancer cells R. Chapman (UK)
09.30-09.50: Immune TME landscape of HRD tumors and their dynamics during cancer evolution D. Dangaj (CH)
09.50-10.10: Discussion
- Garinis G.Professor of Genetics , Department of Biology, University of Crete, Affiliated Group leader at IMBB-FORTH, Greece
- Dangaj D.PhD, Privat Docent (Lecturer), Group Leader, Laboratory Tumor Microenvironment and Biomarker Discovery, Department of oncology UNIL CHUV, Ludwig Institute for Cancer Research Lausanne, Switzerland
- Chapman R.MRC Weatherall Institute of Molecular Medicine, University of Oxford, UK
- Niedzwiedz W.Professor, PhD, Genome Instability and Cancer Team, The Institute of Cancer Research, London, UK
Germline and Somatic mutation rate S. Antonarakis (SUI/GR)
- Antonarakis S.Professor Emeritus, University of Geneva Medical School, Switzerland / MediGenome, Swiss Institute of Genomic Medicine, Geneva, Switzerland
Coffee Break
11.00-11.20: How do you assess homologous recombination (validated clinically) G. Christopoulou (GR)
11.20-11.40: Technical aspects and clinical applications of HRD testing based on AmoyDx pipelines (Molecular Pathologist perspectives) U. Malapelle (IT)
11.40-12.00: Utilizing Pillar Biosciences’ Rapid oncoReveal 4-Gene Methylation Panel to guide the expanded use of PARPi therapy in breast cancer patients E. Christoforou (UK)
12.00-12.20: HRD Testing in Ovarian Cancer: A Molecular Pathologist’s Perspective E. Guerini Rocco (IT)
12.20-12.40: Validating and Selecting the Optimal HRD Assay within a Comprehensive Genomic Profiling (CGP) Panel? E. Papadopoulou (GR)
12.40-12.50: Discussion
- Malapelle U.Associate Professor in School of Medicine, Chair of Predictive Molecular Pathology Laboratory, Department of Public Health of University Federico II of Naples, Naples, Italy
- Guerini Rocco E.Associate Professor of Pathology, Department of Oncology and Hemato-Oncology, University of Milan, and Chair of Molecular Pathology Unit, Division of Pathology, European Institute of Oncology, IRCCS, Milano, Italy
- Christoforou E.Senior Scientist, AstraZeneca, Early Oncology R&D, Translational Medicine Epigenomics, UK
- Christopoulou G.MSc, PhD, Lab Director, Head of Genetics & Genomics Dpt, Genotypos S.A.
- Papadopoulou Eir.PhD, International Laboratory Director, Genekor Medical S.A., Greece
Genome organization in DNA repair pathway choice and mutagenesis E. Soutoglou (UK)
- Soutoglou E.Professor of Genome Stability, Genome Damage and Stability Centre, Sussex University, School of Life Sciences, University of Sussex, Brighton, UK
Light Lunch and Poster View
14.30-14.50: Mechanisms of sensitivity of cancer cells to ATR and CHK1 inhibitors Th. Halazonetis (CH)
14.50-15.10: Signaling replication stress and DNA damage beyond cell boundaries Ph. Pasero (FR)
15.10-15.30: Epigenetic regulation of DDR A. Klinakis (GR)
15.30-15.50: Inherited DNA repair deficiencies G. Stewart (UK)
15.50-16.10: Replication stress of CNV in HRD tumors Th. Rampias (GR)
16.10-16.20: Discussion
- Stewart G.Professor, Department of Cancer and Genomic Sciences, University of Birmingham, UK
- Pasero Ph.Institute of Human Genetics, CNRS and University of Montpellier, France
- Halazonetis T.Professor, Dept of Molecular and Cellular Biology, University of Geneva, Switzerland
- Rampias Th.PhD, Investigator - Assistant Professor Level, Biochemical Research Foundation Academy of Athens (BRFAA), Greece
- Klinakis A.PhD, Investigator - Professor Level, Biochemical Research Foundation Academy of Athens (BRFAA), Greece
08.30-08.50: Updating the therapeutic use of PARPi in ovarian cancer R. Zakopoulou (GR)
08.50-09.10: Updating the therapeutic use of PARPi in breast cancer E. Fountzila (GR)
09.10-09.30: Ομιλία για καρκίνο προστάτου M.Liontos (G)
09.30-09.50: Is agnostic treatment of HRD/GSS-positive tumors with PARPi a therapeutic step forward? V. Anastasopoulou (GR)
09.50-10.00: Discussion
- Anastasopoulou V.Postdoctoral Researcher , Hellenic Oncology Research Group, Athens, Greece
- Liontos M.Assistant Professor, Departmentof Clinical Therapeutics, National and Kapodistrian University of Athens, Greece
- Fountzila E.Medical Oncologist, Clinical Associate Professor, European University Cyprus, St Lukes Hospital, Thessaloniki, Greece
- Zakopoulou R.MD, PhD, Medical Oncologist, Locum Consultant, General Anticancer Hospital “Agioi Anargyroi”, Athens, Greece
10.00-10.20: Detection of oxaliplatin- and cisplatin-DNA lesions requires different global genome repair mechanisms that affect their clinical efficacy J. Loizou (UK)
10.20-10.40: ATR inhibitor-based combinations to overcome PARP inhibitor resistance I. Gounaris (DE)
10.40-11.00: AI Biomarkers of Genomic Instability in Triple Negative Breast Cancer S.J. Sammut (UK)
11.00-11.10: Discussion
- Sammut S.J.MD, PhD, Group Leader, Cancer Dynamics Lab, Consultant Medical Oncologist, The Royal Marsden Hospital, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Chester Beatty Laboratories, London, UK
- Gounaris I.MD, PhD, VP, Head of Clinical Development DNA Damage Response (DDR), Merck KGaA
- Loizou J.Group Leader Divisions of Cancer Therapeutics and Breast Cancer Research | Deputy Director Centre for Target Validation, The Institute of Cancer Research, UK
11.30-11.50: Homologous recombination status of platinum responsiv advanced triple negative breast cancers treated with
olaparib +/- Durvalumab maintenance therapy (Clinical perspective) T. Tan (US)
11.50-12.10: Discovery and preclinical characterisation of saruparib (AZD5305), a PARP1-selective inhibitor and trapper Μ. Albertella (UK)
12.10-12.30: First-in-human Phase 1/2a trial of the first-in-class new PARP1 inhibitor saruparib in patients with advanced solid tumours with HRR mutations» S. Linardopoulos (UK)
12.30-12.50: Tuvusertib (ATR inhibitor) in combination with niraparib or lartesertib (ATM inhibitor): initial safety and efficacy from Ph1b studies I. Gounaris (DE)
12.50-13.00: Discussion
- Tan T.Senior Consultant Medical Oncologist, National Cancer Centre Singapore
- Gounaris I.MD, PhD, VP, Head of Clinical Development DNA Damage Response (DDR), Merck KGaA
- Albertella M.D Phil, Senior Director, Bioscience, AstraZeneca Oncology R&D, Cambridge, UK
- Linardopoulos S.Director, Translational Science, Oncology AstraZeneca, Cambridge, UK
15.00-15.20: Ovarian cancer testing in the UK - a genomics perspective G. Burghel (UK)
15.20-15.40: Telomeric instability in homologous recombination deficiency and cancer S. Gagos (GR)
15.40-16.00: The evolution of combinatorial treatment with PARPi Th. Rampias (GR)
16.00-16.10: Discussion
- Burghel G.Consultant Clinical Scientist, North West Genomic Laboratory Hub) / Honorary Senior Lecturer, University of Manchester, UK
- Gagos S.Principal Investigator Biomedical Research Foundation of the Academy of Athens (BRFAA), Greece
- Rampias Th.PhD, Investigator - Assistant Professor Level, Biochemical Research Foundation Academy of Athens (BRFAA), Greece
